These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7800432)

  • 1. Ventilation-perfusion relationships in preterm infants after surfactant treatment.
    Bowen W; Martin CR; Krauss AN; Auld PA
    Pediatr Pulmonol; 1994 Sep; 18(3):155-62. PubMed ID: 7800432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ventilation-perfusion abnormalities in the preterm infant with hyaline membrane disease: a two-compartment model of the neonatal lung.
    Hand IL; Shepard EK; Krauss AN; Auld PA
    Pediatr Pulmonol; 1990; 9(4):206-13. PubMed ID: 2124345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model of the effect of surfactant treatment on gas exchange in hyaline membrane disease.
    Cotton RB
    Semin Perinatol; 1994 Feb; 18(1):19-22. PubMed ID: 8209282
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of single dose surfactant on pulmonary function.
    Bhat R; Dziedzic K; Bhutani VK; Vidyasagar D
    Crit Care Med; 1990 Jun; 18(6):590-5. PubMed ID: 2111754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf).
    Pfenninger J; Aebi C; Bachmann D; Wagner BP
    Pediatr Pulmonol; 1992 Sep; 14(1):10-5. PubMed ID: 1437337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of surfactant administration influences lung function and gas exchange in a surfactant-deficient rabbit model.
    Krause MF; Schulte-Mönting J; Hoehn T
    Pediatr Pulmonol; 1998 Mar; 25(3):196-204. PubMed ID: 9556012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventilation-perfusion relationships as assessed by a ADN2 in hyaline membrane disease.
    Corbet AJ; Ross JA; Beaudry PH; Stern L
    J Appl Physiol; 1974 Jan; 36(1):74-81. PubMed ID: 4809868
    [No Abstract]   [Full Text] [Related]  

  • 8. The physiologic effects of surfactant treatment on gas exchange in newborn premature infants with hyaline membrane disease.
    Cotton RB; Olsson T; Law AB; Parker RA; Lindstrom DP; Silberberg AR; Sundell HW; Sandberg K
    Pediatr Res; 1993 Oct; 34(4):495-501. PubMed ID: 8255684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease.
    Couser RJ; Ferrara TB; Ebert J; Hoekstra RE; Fangman JJ
    J Pediatr; 1990 Jan; 116(1):119-24. PubMed ID: 2404097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surfactant improves gas mixing and alveolar ventilation in preterm lambs.
    Sandberg K; Edberg KE; Benton W; Silberberg A; Sladek M; Sundell HW
    Pediatr Res; 1991 Aug; 30(2):181-9. PubMed ID: 1896264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenous surfactant replacement therapy of hyaline membrane disease in premature infants.
    Namgung R; Lee C; Suh JS; Park KI; Han DG
    Yonsei Med J; 1989 Dec; 30(4):355-66. PubMed ID: 2697112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of severe hyaline membrane disease with a single-dose of natural exogenous surfactant of porcine origin. A randomized trial: immediate effects and outcome at 28 days of life].
    Walti H; Relier JP; Huon C; Monset-Couchard M; Scemama M; De Gamarra E; Moriette G; Curstedt T; Robertson B
    Arch Fr Pediatr; 1990 May; 47(5):329-34. PubMed ID: 2196030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of positive-pressure breathing on aADN2 in hyaline membrane disease.
    Corbet AJ; Ross JA; Beaudry PH; Stern L
    J Appl Physiol; 1975 Jan; 38(1):33-8. PubMed ID: 234124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial surfactant therapy in hyaline-membrane disease.
    Fujiwara T; Maeta H; Chida S; Morita T; Watabe Y; Abe T
    Lancet; 1980 Jan; 1(8159):55-9. PubMed ID: 6101413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The late administration of surfactant.
    Ballot DE; Rothberg AD; Davies VA
    S Afr Med J; 1995 Jul; 85(7):644-6. PubMed ID: 7482080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS).
    Häfner D; Beume R; Kilian U; Krasznai G; Lachmann B
    Br J Pharmacol; 1995 Jun; 115(3):451-8. PubMed ID: 7582456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The therapeutic use of pulmonary surfactant in neonatal hyaline membrane disease].
    Lozano-González CH; Piña-Ceballos VM; Beyer-Obezo J; Gutiérrez-Martín A; Martínez-Hinojosa B; Flores-Támez ME
    Bol Med Hosp Infant Mex; 1993 Jul; 50(7):481-91. PubMed ID: 8363747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant: a controlled study].
    Sánchez-Mendiola M; Martínez-Natera OC; Herrera-Maldonado N; Ortega-Arroyo J
    Gac Med Mex; 2005; 141(4):267-71. PubMed ID: 16164120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of exogenous surfactant therapy, mechanical ventilation with high end-expiratory pressure and partial liquid ventilation in a model of acute lung injury.
    Hartog A; Vazquez de Anda GF; Gommers D; Kaisers U; Verbrugge SJ; Schnabel R; Lachmann B
    Br J Anaesth; 1999 Jan; 82(1):81-6. PubMed ID: 10325841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial studies of lung volume and VA-Q in hyaline membrane disease.
    Tori CA; Krauss AN; Auld PA
    Pediatr Res; 1973 Feb; 7(2):82-8. PubMed ID: 4688500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.